Hong Kong stocks soar | Hutchmed (China) (00013) rises over 5% again. The company has recently introduced progress in innovative drugs. Institutions say that research and development progress is rapid.

Hutchmed (China) (00013) rose more than 5%, as of publication, up 5.41%, reported at HKD 31.2, with a turnover of HKD 44.2823 million.

Zhitong Finance22:42 ET

U.S. stock abnormality | Northeast securities maintains a "buy" rating, and hutchmed (china) (HCM.US) rose more than 8%.

As of press time, the stock has risen over 8% to $19.245.

Zhitong FinanceJul 12 10:56 ET

HK stocks fluctuation: Hutchmed (China) (00013) rises by more than 9% again, the company recently shared the latest pipeline progress, institutions stated that there are multiple catalysts in the second half of the year.

Hutchmed (China) (00013) rose more than 9%, as of press time, it rose 7.03% to HKD 29.7, with a turnover of HKD 0.114 billion.

Zhitong FinanceJul 11 22:45 ET

Bocom Intl maintains a buy rating for Hutchmed (China) (00013) with a target price of HK$40.

According to the report released by Bocom International on the Zhongtong Finance and Economics App, they maintain buy rating for Hutchmed (China) (00013) with a target price of HKD 40. The report stated that the catalysts for the second half of 2024 include global sales of Fruquintinib and domestic approval progress based on Frutiga research for 2L gastric cancer as well as global declaration based on SAVANNAH research for Savolitinib. The domestic approval for Surufatinib was also mentioned. The bank pointed out that the effectiveness of the combination therapy of Sulfatinib and PD-1 for pancreatic cancer treatment is encouraging. One IIT data announced at ASCO GI conference showed that the combination of Sulfatinib and AS therapy is

Zhitong FinanceJul 10 22:13 ET

BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $29

BofA Securities analyst Alec Stranahan maintains $Hutchmed (China)(HCM.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 46.2%

Moomoo NewsJul 10 05:34 ET · Ratings

Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).

Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.

Zhitong FinanceJul 8 20:58 ET